Table 3.

Pathologic complete response rates by PIK3CA status in different neoadjuvant regimens

RegimensTotal (n)Non-pCR, n (%)pCR, n (%)Pa
Anthracycline (n = 265)
 Mutant6455 (85.9)9 (14.1)0.33
 Wild-type201162 (80.6)39 (19.4)
Anthracycline-taxane (n = 317)
 Mutant9483 (88.3)11 (11.7)0.009
 Wild-type223168 (75.3)55 (24.7)
Taxane (n = 100)
 Mutant3126 (83.9)5 (16.1)0.74
 Wild-type6956 (81.2)13 (18.8)
Others (n = 47)
 Mutant1712 (70.6)5 (29.4)0.46
 Wild-type3025 (83.3)5 (16.7)
  • aPIK3CA mutant compared with wild-type.